Skip to main content
main-content

ESC Congress 2021

27 – 30 AUGUST
ESC 2021 Congress news

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Heart pills

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

ESC 2021 interviews

09-15-2021 | ESC 2021 | Conference coverage | Video

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

Research news from ESC 2021

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits